Grazoprevir
- Generic Name
- Grazoprevir
- Brand Names
- Zepatier
- Drug Type
- Small Molecule
- Chemical Formula
- C38H50N6O9S
- CAS Number
- 1350514-68-9
- Unique Ingredient Identifier
- 8YE81R1X1J
- Background
Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% o...
- Indication
Grazoprevir is indicated in combination with Elbasvir (as the fixed dose combination product Zepatier) with or without Ribavirin for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
- Associated Conditions
- Chronic Hepatitis C Genotype 1, Chronic hepatitis C genotype 1a, Genotype 4 Chronic Hepatitis C
- Associated Therapies
- -
Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02601573
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Valme University Hospital
- Target Recruit Count
- 1128
- Registration Number
- NCT02333292
- Locations
- 🇪🇸
Valme University Hospital, Seville, Andalusia, Spain
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 443
- Registration Number
- NCT02332707
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 413
- Registration Number
- NCT02332720
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 399
- Registration Number
- NCT02203149
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02115321
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 237
- Registration Number
- NCT02092350
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01937975
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 98
- Registration Number
- NCT01932762
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 573
- Registration Number
- NCT01717326
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath